2. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. Ann N Y Acad Sci 2010;1202:237–43.
3. Kosaryan M, Vahidshahi K, Jamali AE, Sarparast L. Bone mineral density (BMD) of patients with beta thalassemia, Thalassemia Research Center 2007. J MazandaranUniv Med Sci 2012;21:63–73.
4. Naderi M, Zakeri Z, Dorgalaleh A, Alizadeh SH, Tabibian SH, Bamedi T. Effect of pamidronate on osteoporosis in patients with β-thalassemia major. IJBC 2014;6:149–53.
7. Bekheirnia MR, Shamshirsaz AA, Kamgar M, Bouzari N, Erfanzadeh G, Pourzahedgilani N, et al. Serum zinc and its relation to bone mineral density in beta-thalassemic adolescents. Biol Trace Elem Res 2004;97:215–24.
9. Patıroğlu T, Altuner Torun Y, Kula M, Karakükçü M. Treatment of thalassemia-induced osteoporosis with intermittent pamidronate infusions: two-year follow up. Turk J Haematol 2008;25:79–82.
10. Fung EB. Nutritional deficiencies in patients with thalassemia. Ann N Y Acad Sci 2010;1202:188–96.
14. Tantawy AA, El Kholy M, Moustafa T, Elsedfy HH. Bone mineral density and calcium metabolism in adolescents with beta-thalassemia major. Pediatr Endocrinol Rev 2008;6 Suppl 1:132–5.
15. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C, et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 2002;291:680–6.
17. Izadyar S, Fazeli M, Izadyar M, Salamati P, Gholamrezanezhad A. Bone mineral density in adult patients with major thalassaemia: our experience and a brief review of the literature. Endokrynol Pol 2012;63:264–9.